Publications & News

WilmerHale Advises Argos Therapeutics in Pricing of $50M Public Offering

July 28, 2016

Argos Therapeutics, Inc., an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, announced the pricing of its public offering of $50 million. 

The WilmerHale team was led by Partner Stuart Falber and included Associate Leora Rodenstein, Senior Associate Ryan Mitteness, Associate Andrea Sorrentino, Attorney Heidi Treiber and Senior Associate Mia Kelley. Partner Julie Hogan Rodgers and Associate Leah Segal (Tax) were also involved.

Read Argos Therapeutics' press release for more information.